Peripheral blood miR‑372 as a biomarker for ulcerative colitis via direct targeting of NLRP12

  • Authors:
    • Mengdie Shen
    • Li'na Meng
  • View Affiliations

  • Published online on: June 25, 2019     https://doi.org/10.3892/etm.2019.7707
  • Pages: 1486-1492
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

The present study aimed to investigate the expression pattern and underlying mechanism of microRNA‑372 (miR‑372) in the progression of ulcerative colitis (UC). Reverse transcription‑quantitative polymerase chain reaction was used to measure miR‑372 expression levels in the blood and colonic mucosa tissue samples from patients with UC. The present study demonstrated that levels of miR‑372 were significantly increased in the blood and colonic mucosa tissue samples from patients with UC compared with healthy controls. Furthermore, the level of serum miR‑372 was positively correlated with the level of serum c‑reactive protein. Receiver operating characteristic analysis indicated that levels of miR‑372 detected in serum and tissue samples could be used to screen for patients with UC from healthy controls. These results indicated a potential role of miR‑372 as a diagnostic marker and therapeutic target for patients with UC. Furthermore, a conserved miR‑372 binding site in the 3'untranslated region of the NLR family pyrin domain containing 12 (NLRP12) was identified. Dual luciferase assay demonstrated that overexpression of miR‑372 significantly reduced the relative luciferase activity of pmirGLO‑NLRP12‑3'UTR compared with control pmirGLO. In addition, western blot analysis indicated that overexpression of miR‑372 significantly decreased the protein expression level of NLRP12. Therefore it was hypothesized that miR‑372 may promote the progression of UC by suppressing NLRP12 protein expression and thereby inducing the excessive production of inflammatory cytokines. In conclusion, high levels of miR‑372 detected in peripheral blood samples may serve a role as a potential biomarker to screen potential patients with UC from healthy controls.
View Figures
View References

Related Articles

Journal Cover

August-2019
Volume 18 Issue 2

Print ISSN: 1792-0981
Online ISSN:1792-1015

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Shen M and Shen M: Peripheral blood miR‑372 as a biomarker for ulcerative colitis via direct targeting of NLRP12. Exp Ther Med 18: 1486-1492, 2019
APA
Shen, M., & Shen, M. (2019). Peripheral blood miR‑372 as a biomarker for ulcerative colitis via direct targeting of NLRP12. Experimental and Therapeutic Medicine, 18, 1486-1492. https://doi.org/10.3892/etm.2019.7707
MLA
Shen, M., Meng, L."Peripheral blood miR‑372 as a biomarker for ulcerative colitis via direct targeting of NLRP12". Experimental and Therapeutic Medicine 18.2 (2019): 1486-1492.
Chicago
Shen, M., Meng, L."Peripheral blood miR‑372 as a biomarker for ulcerative colitis via direct targeting of NLRP12". Experimental and Therapeutic Medicine 18, no. 2 (2019): 1486-1492. https://doi.org/10.3892/etm.2019.7707